A recent breakthrough randomized, placebo-controlled trial found that fluvoxamine significantly reduces debilitating long COVID fatigue with a remarkably low 20.0% adverse event rate, providing clinicians with a potent new tool against post-viral exhaustion. Key Clinical Findings of the Study Include:• Fluvoxamine Efficacy: The study demonstrated that fluvoxamine produced a statistically significant reduction in fatigue by day 60, with these improvements remaining durable through the 90-day follow-up. • Quality of Life: In the study, consistent enhancements in overall well-being and life quality were reported by participants in the fluvoxamine group at every assessment point, a trend not mirrored in the metformin or placebo cohorts. The results suggest that fluvoxamine is a superior candidate for treating long COVID fatigue, as evidenced by its 20.0% adverse event rate and its capacity to provide sustained symptomatic relief compared to both metformin and placebo. The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial.